(Q40626611)

22 September 2017

Antitumour activity of the silybin-phosphatidylcholine complex, IdB 1016, against human ovarian cancer (English)

1 reference

22 September 2017

1 reference

1 reference

1 reference

https://api.crossref.org/works/10.1016/S0959-8049(03)00624-5

21 March 2024

1

D. Gallo

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A14556934

21 March 2024

10

G. Scambia

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A14556934

21 March 2024

author name string

S. Giacomelli

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A14556934

21 March 2024

C. Ferlini

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A14556934

21 March 2024

G. Raspaglio

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A14556934

21 March 2024

P. Apollonio

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A14556934

21 March 2024

S. Prislei

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A14556934

21 March 2024

A. Riva

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A14556934

21 March 2024

P. Morazzoni

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A14556934

21 March 2024

E. Bombardelli

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A14556934

21 March 2024

language of work or name

English

1 reference

National Center for Biotechnology Information

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=14556934

21 March 2024

publication date

1 November 2003

1 reference

full work available at URL

22 September 2017

https://api.elsevier.com/content/article/PII:S0959804903006245?httpAccept=text/xml

1 reference

https://api.crossref.org/works/10.1016/S0959-8049(03)00624-5

https://api.elsevier.com/content/article/PII:S0959804903006245?httpAccept=text/plain

21 March 2024

1 reference

https://api.crossref.org/works/10.1016/S0959-8049(03)00624-5

European Journal of Cancer

21 March 2024

published in

1 reference

22 September 2017

39

1 reference

22 September 2017

16

1 reference

22 September 2017

2403-2410

1 reference

22 September 2017

Cancer statistics, 2002

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2803%2900624-5

7 January 2021

Second-line treatment of ovarian cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2803%2900624-5

7 January 2021

Comparative bioavailability of Silipide, a new flavanolignan complex, in rats

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2803%2900624-5

7 January 2021

Pharmacokinetic studies on IdB 1016, a silybin- phosphatidylcholine complex, in healthy human subjects

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2803%2900624-5

7 January 2021

Antiproliferative effect of silybin on gynaecological malignancies: synergism with cisplatin and doxorubicin

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2803%2900624-5

7 January 2021

Inhibition of human carcinoma cell growth and DNA synthesis by silibinin, an active constituent of milk thistle: comparison with silymarin

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2803%2900624-5

7 January 2021

CDK inhibitors: cell cycle arrest versus apoptosis

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2803%2900624-5

7 January 2021

Antiproliferative and apoptotic effects of silibinin in rat prostate cancer cells

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2803%2900624-5

7 January 2021

Silybin and its bioavailable phospholipid complex (IdB 1016) potentiate in vitro and in vivo the activity of cisplatin

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2803%2900624-5

7 January 2021

Anti-angiogenic potential of a cancer chemopreventive flavonoid antioxidant, silymarin: inhibition of key attributes of vascular endothelial cells and angiogenic cytokine secretion by cancer epithelial cells

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2803%2900624-5

7 January 2021

Vascular endothelial growth factor (VEGF) in human breast cancer: Correlation with disease-free survival

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2803%2900624-5

7 January 2021

DNA arrays for analysis of gene expression

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2803%2900624-5

7 January 2021

Antiangiogenic effects of a protein kinase Cbeta-selective small molecule

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2803%2900624-5

7 January 2021

Characterization and expression of a novel alternatively spliced human angiopoietin-2

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2803%2900624-5

7 January 2021

Structure and expression of a novel member, FGF-16, on the fibroblast growth factor family

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2803%2900624-5

7 January 2021

Tumor growth of FGF or VEGF transfected MCF-7 breast carcinoma cells correlates with density of specific microvessels independent of the transfected angiogenic factor

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2803%2900624-5

7 January 2021

Novel VEGF family members: VEGF-B, VEGF-C and VEGF-D.

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2803%2900624-5

7 January 2021

VEGFR-3 and its ligand VEGF-C are associated with angiogenesis in breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2803%2900624-5

7 January 2021

Signaling vascular morphogenesis and maintenance

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2803%2900624-5

7 January 2021

Angiopoietin-2, a natural antagonist for Tie2 that disrupts in vivo angiogenesis

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2803%2900624-5

7 January 2021

Vessel cooption, regression, and growth in tumors mediated by angiopoietins and VEGF.

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2803%2900624-5

7 January 2021

Expressional regulation of angiopoietin-1 and -2 and the tie-1 and -2 receptor tyrosine kinases during cutaneous wound healing: a comparative study of normal and impaired repair

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2803%2900624-5

7 January 2021

The pursuit of optimal outcomes in cancer therapy in a new age of rationally designed target-based anticancer agents

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2803%2900624-5

7 January 2021

Silibinin up-regulates insulin-like growth factor-binding protein 3 expression and inhibits proliferation of androgen-independent prostate cancer cells

7

1 reference

https://api.crossref.org/works/10.1016/S0959-8049(03)00624-5

Dietary feeding of silibinin inhibits advance human prostate carcinoma growth in athymic nude mice and increases plasma insulin-like growth factor-binding protein-3 levels

21 March 2024

8

1 reference

https://api.crossref.org/works/10.1016/S0959-8049(03)00624-5

Silybin inhibition of human T-lymphocyte activation

21 March 2024

29

1 reference

https://api.crossref.org/works/10.1016/S0959-8049(03)00624-5

Treatment of silymarin, a plant flavonoid, prevents ultraviolet light-induced immune suppression and oxidative stress in mouse skin

21 March 2024

30

1 reference

https://api.crossref.org/works/10.1016/S0959-8049(03)00624-5

21 March 2024

Identifiers

1 reference

22 September 2017

1 reference